（来源：海特生物）

转自：海特生物

在2025年12月6日-9日在美国奥兰多召开的67th ASH Annual Meeting and Exposition（美国血液学年会，以下简称ASH）期间，注射用埃普奈明（aponermin 商品名:沙艾特®）4篇壁报亮相ASH会场Orange County Convention Center，west halls B3-B4。

PRESENTATION ID 2270

Safety and Efficacy of Aponermin-based Chemotherapy as Bridging therapy before CAR-T Cell Treatment in Relapsed/Refractory Multiple Myeloma

Huanxin Zhang1，Yi Wang2，Chengcheng Fu3，Yanli Feng2，Yang Liu1，Jing Wang3, Chunrui Li4，Wenming Chen5，ZhenYu Li1#

1.The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

2.Shaanxi Provincial People's Hospital, Xi’an, China

3.The First Affiliated Hospital of Soochow University, Suzhou, China

4.Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

5.Beijing Chao Yang Hospital, Beijing, China

PRESENTATION ID 2271

Efficacy and Safety of Aponermin-Carfilzomib-Dexamethasone-based regimens for Relapsed/ Refractory Multiple Myeloma: A Phase 2 Prospective Multi-center Study

Huixing Zhou1, Chunrui Li2, Baijun Fang3, Lingzhi Yan4, Aijun Liu1, Peiling Zhang2, Yang Liu5, Xiaoqi Qin6, huanxin Zhang5, Wei Zhou7, Hong-hu Zhu1, Leng Yun1, Yin Wu1, Yi Wang7, Wenming Chen1, Guangzhong Yang1

1.Beijing Chao Yang Hospital. 

2.Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. 

3.Henan Cancer Hospital. 

4.The First Affiliated Hospital of Soochow University. 

5.The Affiliated Hospital of Xuzhou Medical University.6.Second hospital of Shanxi Medical University. 7.Shaanxi Provincial People's Hospital.

PRESENTATION ID 2276

Aponermin Combined with Carfilzomib - Pomalidomide - Dexamethasone (KPd) in Patients with Relapsed or Refractory Multiple Myeloma: a Prospective, Open-Label, Multicenter Study

Jing Chen1, Donghua He1, Xiaoyan Han1, Mingming Zhang1, Li Yang1, Haimeng Yan1, Lai Jin2, He Huang1, Juan Du3, Aijun Liu4, Zhen Cai1

1.The First Affiliated Hospital, Zhejiang University, School of Medicine, Bone Marrow Transplantation Center, Hangzhou, Zhejiang, China 

2.Zhejiang Provincial People’s Hospital, Hangzhou, China

3.Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China; Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

4.Beijing Chao. Yang Hospital, Capital Medical University, Beijing, China

PRESENTATION ID 2280

Phase 2 Study of Aponermin +KT-DECP in Patients with Relapsed/Refractory Multiple Myeloma and Extramedullary Disease

Menghan Liu1, Xiaoqi Qin2, Weiwei Tian3, Yuechen Zhang1, Yanru Zhang1, Lefu Huang1, Wenjing Li1, Jingrong Wang4, Yanping Ma2, Liping Su4, Yan Yan5, Aijun Liao6, Wenming Chen1, Aijun Liu1

1.Chao Yang Hospital Affiliated with Capital Medical University, Beijing, China

2.Second hospital of Shanxi Mecical University, Taiyuan, China

3.Shanxi Bethune Hospital, Taiyuan,China

4.Shanxi Cancer Hospital, Taiyuan, China

5.Bayannur Hospital, Bayannur, China

6.Shengjing Hospital of China Medical University, Shenyang, China

据统计，本次ASH 2025共计收录9篇埃普奈明相关摘要，其中4篇为POSTER展示。根据本次会议已收录的真实世界数据显示，埃普奈明可与多种MM治疗方案联合，在多线复发、伴有髓外浆细胞瘤（EMP）、细胞遗传学高危、免疫治疗后复发患者中，获得了令人鼓舞的疗效，且安全性可控。

2025年ASH年会注射用埃普奈明收录情况一览